208 related articles for article (PubMed ID: 12595916)
1. Pharmacology of the ACAT inhibitor avasimibe (CI-1011).
Llaverías G; Laguna JC; Alegret M
Cardiovasc Drug Rev; 2003; 21(1):33-50. PubMed ID: 12595916
[TBL] [Abstract][Full Text] [Related]
2. Acyl-coenzyme A:cholesterol acyltransferase inhibitor, avasimibe, stimulates bile acid synthesis and cholesterol 7alpha-hydroxylase in cultured rat hepatocytes and in vivo in the rat.
Post SM; Zoeteweij JP; Bos MH; de Wit EC; Havinga R; Kuipers F; Princen HM
Hepatology; 1999 Aug; 30(2):491-500. PubMed ID: 10421659
[TBL] [Abstract][Full Text] [Related]
3. Avasimibe Pfizer.
Burnett JR; Huff MW
Curr Opin Investig Drugs; 2002 Sep; 3(9):1328-33. PubMed ID: 12498009
[TBL] [Abstract][Full Text] [Related]
4. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits.
Bocan TM; Krause BR; Rosebury WS; Mueller SB; Lu X; Dagle C; Major T; Lathia C; Lee H
Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):70-9. PubMed ID: 10634802
[TBL] [Abstract][Full Text] [Related]
5. Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.
Worthley SG; Helft G; Corti R; Worthley MI; Chew DP; Fayad ZA; Zaman AG; Fallon JT; Fuster V; Badimon JJ
Pathophysiol Haemost Thromb; 2007; 36(1):9-17. PubMed ID: 18332609
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
J Lipid Res; 1999 Jul; 40(7):1317-27. PubMed ID: 10393217
[TBL] [Abstract][Full Text] [Related]
7. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice.
Delsing DJ; Offerman EH; van Duyvenvoorde W; van Der Boom H; de Wit EC; Gijbels MJ; van Der Laarse A; Jukema JW; Havekes LM; Princen HM
Circulation; 2001 Apr; 103(13):1778-86. PubMed ID: 11282910
[TBL] [Abstract][Full Text] [Related]
8. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions.
Tardif JC; Grégoire J; L'Allier PL; Anderson TJ; Bertrand O; Reeves F; Title LM; Alfonso F; Schampaert E; Hassan A; McLain R; Pressler ML; Ibrahim R; Lespérance J; Blue J; Heinonen T; Rodés-Cabau J;
Circulation; 2004 Nov; 110(21):3372-7. PubMed ID: 15533865
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
Lee HT; Sliskovic DR; Picard JA; Roth BD; Wierenga W; Hicks JL; Bousley RF; Hamelehle KL; Homan R; Speyer C; Stanfield RL; Krause BR
J Med Chem; 1996 Dec; 39(26):5031-4. PubMed ID: 8978833
[No Abstract] [Full Text] [Related]
10. The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression.
Bocan TM; Krause BR; Rosebury WS; Lu X; Dagle C; Bak Mueller S; Auerbach B; Sliskovic DR
Atherosclerosis; 2001 Jul; 157(1):97-105. PubMed ID: 11427208
[TBL] [Abstract][Full Text] [Related]
11. Preclinical safety evaluation of avasimibe in beagle dogs: an ACAT inhibitor with minimal adrenal effects.
Robertson DG; Breider MA; Milad MA
Toxicol Sci; 2001 Feb; 59(2):324-34. PubMed ID: 11158726
[TBL] [Abstract][Full Text] [Related]
12. Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor.
Taghibiglou C; Van Iderstine SC; Kulinski A; Rudy D; Adeli K
Biochem Pharmacol; 2002 Feb; 63(3):349-60. PubMed ID: 11853686
[TBL] [Abstract][Full Text] [Related]
13. The ACAT inhibitor avasimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs.
Burnett JR; Telford DE; Barrett PH; Huff MW
Biochim Biophys Acta; 2005 Dec; 1738(1-3):10-8. PubMed ID: 16427354
[TBL] [Abstract][Full Text] [Related]
14. Effect of the ACAT inhibitor, HL-004, on cholesterol metabolism in macrophages.
Murakami S; Yamagishi I; Asami Y; Sato M; Tomisawa K
Cell Mol Biol (Noisy-le-grand); 1996 Sep; 42(6):865-72. PubMed ID: 8891354
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of acyl-coenzyme a: cholesterol acyltransferase.
Miyazaki A; Kanome T; Watanabe T
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):463-9. PubMed ID: 16503866
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia.
Insull W; Koren M; Davignon J; Sprecher D; Schrott H; Keilson LM; Brown AS; Dujovne CA; Davidson MH; McLain R; Heinonen T
Atherosclerosis; 2001 Jul; 157(1):137-44. PubMed ID: 11427213
[TBL] [Abstract][Full Text] [Related]
17. Divergent pharmacologic activities of PD 132301-2 and CL 277,082, urea inhibitors of acyl-CoA:cholesterol acyltransferase.
Krause BR; Black A; Bousley R; Essenburg A; Cornicelli J; Holmes A; Homan R; Kieft K; Sekerke C; Shaw-Hes MK
J Pharmacol Exp Ther; 1993 Nov; 267(2):734-43. PubMed ID: 8246149
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of acyl-CoA:cholesterol O-acyltransferase. synthesis and pharmacological activity of (+/-)-2-dodecyl-alpha-phenyl-N-(2,4,6-trimethoxyphenyl)-2H-tetrazole-5- acetamide and structurally related tetrazole amide derivatives.
O'Brien PM; Sliskovic DR; Picard JA; Lee HT; Purchase CF; Roth BD; White AD; Anderson M; Mueller SB; Bocan T; Bousley R; Hamelehle KL; Homan R; Lee P; Krause BR; Reindel JF; Stanfield RL; Turluck D
J Med Chem; 1996 Jun; 39(12):2354-66. PubMed ID: 8691430
[TBL] [Abstract][Full Text] [Related]
19. Acyl-coenzyme A:cholesterol acyltransferase inhibitors for controlling hypercholesterolemia and atherosclerosis.
Miyazaki A; Sakai M; Sakamoto Y; Horiuchi S
Curr Opin Investig Drugs; 2003 Sep; 4(9):1095-9. PubMed ID: 14582454
[TBL] [Abstract][Full Text] [Related]
20. Anti-atherogenic effects of the acyl-CoA:cholesterol acyltransferase inhibitor, avasimibe (CI-1011), in cultured primary human macrophages.
Rodriguez A; Usher DC
Atherosclerosis; 2002 Mar; 161(1):45-54. PubMed ID: 11882316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
